Expression of CD44 and CD24 in tumor tissue from patients with prostate cancer
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The aim was to evaluate the prognostic value CD44 and CD24 stem cells of tumor markers in prostate tissue after radical prostatectomy in 102 patients with prostate cancer.
Immunohistochemical study (IHC) expression of CD24 and CD44 in primary antibodies using monoclonal antibodies (clone SN3b, Thermo Scientific, USA), and CD44/HCAM (clone 156 3C11, Diagnostic BioSystems, USA). The positive expression of CD24 and CD44 was considered the number of immunopositive cells for more than 10%. To visualize the results of IHC reagents used EnVision system (Dako LSAB2 system, Denmark). Histological sections were stained with Mayer’s hematoxylin. The results are analyzed using an optical microscope XSP 137 BP (firm JNOEC, Ч200 400).
The correlation between the expression of CD24 and CD44, and stage of disease. When PSA levels >15 ng/mL was an increase expression markers. There was a correlation between expression CD44+ and CD24 , and the emergence of biochemical recurrence (r=0,4; p<0,05). Determination of cells in the tumor tissue markers CD44+CD24 /low can be additional criterion for prognosis of prostate cancer.
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Zhang K Zhou S, Wang L, Wang J, et al., Current Stem Cell Biomarkers and Their Functional Mechanisms in Prostate Cancer. Int J Mol Sci. 2016 Jul 19;17(7).
Hurt E.M., Kawasaki B.T., Klarmann G.J., Thomas S.B. et al. CD44+CD24ґ prostate cells are early cancer progenitor stem cells that provide a model for patients with poor prognosis. Br. J. Cancer 2008, 98, 756–765.
Zhang XH, Sakamoto H, Takenaka I. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Br J Urol 1996; 77: 441-444.
Vis AN, Noordzij MA, Fitoz K, et al. Prognostic value of cell cycle proteins p27(kip1) and MIB 1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol 2000; 164: 2156-2161.
Kallakury BV, Sheehan CE, Ambros RA, et al. Correlation of p34cdc2 cyclin dependent kinase over expression, CD44s downregulation, and HER 2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. J Clin Oncol 1998; 16: 1302-1309.
Makarewicz R, Zyromska A, Andrusewicz H. Comparative analysis of biological profiles of benign prostate hyperplasia and prostate cancer as potential diagnostic, prognostic and predictive indicators. Folia Histochem Cytobiol 2011; 49: 452-457.
Korski K., Malicka Durczak A., Brкborowicz J. / Expression of stem cell marker CD44 in prostate cancer biopsies predicts cancer grade in radical prostatectomy specimens // Pol J Pathol 2014; 65 (4): 291 295.
Ugolkov AV, Eisengart LJ, Luan C, Yang XJ. Expression analysis of putative stem cell markers in human benign and malignant prostate. Prostate 2011; 71: 18-25.
C. Liu, K. Kelnar, B. Liu et al. The microRNA miR 34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, Nature Medicine, vol. 17, no. 2, pp. 211–216, 2011.
